Limula SA

At Limula, we want to make ex vivo gene-engineered cell therapies accessible to patients in need. To fulfil this vision, we offer a unique platform technology that can perform every step of the cell therapy manufacturing process in a single device, co-located at the hospital. With our solution, we increase overall safety and reproducibility of the process by automating unnecessary manual steps; we remove the need for large sterile facilities that are expensive to build and maintain, and for long-distance cryogenic transport of fragile human samples; we lower the number of human operators and, as a consequence, decrease costs to treat patients. Our technology has the potential to catalyse the transition towards the widespread adoption of highly personalised treatments, and radically broaden their accessibility